42 related articles for article (PubMed ID: 10843749)
1. Engineered acid-stabile human interferon gamma.
Kontsek P; Waschütza G; Kontseková E; Otto B
Cytokine; 2000 Jun; 12(6):708-10. PubMed ID: 10843749
[TBL] [Abstract][Full Text] [Related]
2. Low pH does not rearrange antigenic structure of porcine interferon gamma but inhibits its receptor binding.
Vancová I; Martens E; Vandenbroeck K; Kontseková E; Billiau A; Kontsek P
Acta Virol; 2000 Apr; 44(2):121-2. PubMed ID: 10989704
[No Abstract] [Full Text] [Related]
3. Amended recombinant cells (ARCs): an economical and surprisingly effective production and delivery vehicle for recombinant bovine IFN-gamma.
Gaertner FH; Babiuk LA; Van Moorlehem EA; Beskorwayne TK; Lee SL; Shutter RW; Armstrong JM; Griebel PJ
J Control Release; 2005 Oct; 107(2):189-202. PubMed ID: 16019101
[TBL] [Abstract][Full Text] [Related]
4. Methods for preparation of recombinant cytokine proteins V. mutant analogues of human interferon-gamma with higher stability and activity.
Pechenov SE; Tikhonov RV; Shingarova LN; Korobko VG; Yakimov SA; Klyushnichenko VE; Babajantz AA; Beliaev DL; Kuznetzov VP; Shvetz VI; Wulfson AN
Protein Expr Purif; 2002 Mar; 24(2):173-80. PubMed ID: 11858710
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies to guinea pig interferon-gamma: tools for cytokine detection and neutralization.
Schäfer H; Kliem G; Kropp B; Burger R
J Immunol Methods; 2007 Dec; 328(1-2):106-17. PubMed ID: 17905302
[TBL] [Abstract][Full Text] [Related]
6. [Antiviral activity determination of recombinant equine interferon-gamma and identification inhibited antiviral activity of monoclonal antibodies].
Bai Y; Chen W; Tong T; Zhang W; Xu S; Wang Q; Sun Q; Liu G; Bu Z; Wu D
Sheng Wu Gong Cheng Xue Bao; 2008 Jul; 24(7):1258-62. PubMed ID: 18837405
[TBL] [Abstract][Full Text] [Related]
7. Production of biological active murine IFN-gamma by recombinant Lactococcus lactis.
Bermúdez-Humarán LG; Cortes-Perez NG; L'Haridon R; Langella P
FEMS Microbiol Lett; 2008 Mar; 280(2):144-9. PubMed ID: 18248432
[TBL] [Abstract][Full Text] [Related]
8. Prolonging the half-life of human interferon-alpha 2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7- interferon-alpha 2.
Shechter Y; Preciado-Patt L; Schreiber G; Fridkin M
Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1212-7. PubMed ID: 11158619
[TBL] [Abstract][Full Text] [Related]
9. Reversibility of acid denaturation of recombinant interferon-gamma.
Arakawa T; Hsu YR; Narachi MA; Herrera C; Rohde MF; Hennigan P
Biopolymers; 1990; 29(6-7):1065-8. PubMed ID: 2164426
[TBL] [Abstract][Full Text] [Related]
10. A simple, rapid and large capacity ELISA for biologically active native and recombinant human IFN gamma.
Gallati H; Pracht I; Schmidt J; Häring P; Garotta G
J Biol Regul Homeost Agents; 1987; 1(3):109-18. PubMed ID: 3140597
[TBL] [Abstract][Full Text] [Related]
11. Characterisation and quantification of equine interferon gamma.
Gutmann S; Zawatzky R; Müller M
Vet Immunol Immunopathol; 2005 Mar; 104(1-2):105-15. PubMed ID: 15661336
[TBL] [Abstract][Full Text] [Related]
12. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency.
Dupuis S; Jouanguy E; Al-Hajjar S; Fieschi C; Al-Mohsen IZ; Al-Jumaah S; Yang K; Chapgier A; Eidenschenk C; Eid P; Al Ghonaium A; Tufenkeji H; Frayha H; Al-Gazlan S; Al-Rayes H; Schreiber RD; Gresser I; Casanova JL
Nat Genet; 2003 Mar; 33(3):388-91. PubMed ID: 12590259
[TBL] [Abstract][Full Text] [Related]
13. Fas- and interferon gamma-induced apoptosis in Chang conjunctival cells: further investigations.
De Saint Jean M; Debbasch C; Rahmani M; Brignole F; Feldmann G; Warnet JM; Baudouin C
Invest Ophthalmol Vis Sci; 2000 Aug; 41(9):2531-43. PubMed ID: 10937564
[TBL] [Abstract][Full Text] [Related]
14. ELISA measurement of interferons.
Garrison TL; Hung F; Izotova L; Schwartz B; Lavoie T; Lee-Own FV
Biotechniques; 2002 Oct; Suppl():98-100. PubMed ID: 12395933
[No Abstract] [Full Text] [Related]
15. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
[TBL] [Abstract][Full Text] [Related]
16. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta.
Meager A; Das RG
J Immunol Methods; 2005 Nov; 306(1-2):1-15. PubMed ID: 16226271
[TBL] [Abstract][Full Text] [Related]
17. Design, characterization, and structure of a biologically active single-chain mutant of human IFN-gamma.
Landar A; Curry B; Parker MH; DiGiacomo R; Indelicato SR; Nagabhushan TL; Rizzi G; Walter MR
J Mol Biol; 2000 May; 299(1):169-79. PubMed ID: 10860730
[TBL] [Abstract][Full Text] [Related]
18. Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega-interferon produced from CHO-SS cells.
Buckwold VE; Lang W; Scribner C; Blanchett D; Alessi T; Langecker P
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):62-70. PubMed ID: 16867173
[TBL] [Abstract][Full Text] [Related]
19. Biological activity of hamster interferon-gamma is modulated by the carboxyl-terminal tail.
Zhao W; Valencia AZ; Melby PC
Cytokine; 2006 Jun; 34(5-6):243-51. PubMed ID: 16843003
[TBL] [Abstract][Full Text] [Related]
20. IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.
Carlo-Stella C; Guidetti A; Di Nicola M; Lavazza C; Cleris L; Sia D; Longoni P; Milanesi M; Magni M; Nagy Z; Corradini P; Carbone A; Formelli F; Gianni AM
Cancer Res; 2007 Apr; 67(7):3269-75. PubMed ID: 17409435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
